DBV screens first patient in VITESSE Phase 3 peanut allergy trial for ages 4–7

DBV Technologies S.A.

First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois for VITESSE Phase 3 trial.
Trial enrolls 600 children ages 4–7, randomized 2:1 active (Viaskin Peanut 250 µg) vs placebo.
Primary efficacy endpoint is treatment response rate at Month 12; last patient screening expected 1H 2024.
Topline results anticipated in 1H 2025; FDA supports study to potentially support BLA submission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.